Corporate Communications app for iPhone, iPad and Android – theCOMMSapp

Wound Management Technologies Launches Free Investor Relations App

Wound Management Technologies Launches Free Investor Relations App

ADDISON, TX–(Marketwired – Sep 16, 2014) – Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that the Company released an investor relations app for the iPhone, iPad and Android mobile devices.

The free app can be downloaded at the Apple app store for the iPhone and iPad at or at Google Play for Android mobile devices at

Wound Management’s investor relations app, which is powered by theIRapp®, allows users to directly access and easily navigate through the Company’s investor relations materials, as well as obtain a stock quote and other important Company information. The app features recent press releases, SEC filings, the investor presentation, and company fact sheet. Marketing material, conference call transcripts and upcoming events can also be accessed via the app. Investors receive a push notification when new information is posted by the Company. There is also a sharing functionality with email, Twitter and Facebook that can further facilitate news flow.

“We are very excited to be one of the early adopters of this mobile technology as we focus on gaining broader awareness throughout the investment community. The company continues to execute on its strategic growth initiatives and the IR app will help investors keep informed of our progress,” commented Robert Lutz, Jr., Chief Executive Officer of Wound Management Technologies. “The immediate access to financial and corporation information provided by the app will only increase shareholder value for our investors.”

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX® which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information

Information about Forward-Looking Statements
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300 /

Read the original article here: